Langenfeld, Germany, June 03, 2026 (GLOBE NEWSWIRE) -- Booking Health today announced the release of findings examining international patient access to personalized dendritic cell therapy for glioblastoma in Germany. The findings, based on a documented Canadian patient case and supporting clinical research, highlight how cross-border treatment pathways may provide patients with aggressive brain tumors access to individualized immunotherapy options that are not widely available within all healthcare systems.
NEWTON, Mass., June 3, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it...
ProBio and GCP ClinPlus today announced a strategic collaboration designed to accelerate Investigator-Initiated Trials (IITs) in China and provide integrated, end-to-end clinical and development...
MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2
GENEVA, June 3, 2026 /PRNewswire/ -- MindMaze Therapeutics Holding SA (SIX: MMTX) (MindMaze Therapeutics or the Company), a global leader in scalable precision neurotherapeutics,...
Warsaw, Poland – June 03, 2026 – JJP Biologics, ("JJPBio" or the "Company") a clinical-stage, immune-focused biotech that engineers precision antibodies to correct derailed immune pathways that drive autoimmune diseases and cancer, today announces positive interim data from its ongoing Phase 1b trial evaluating nebaprubart, also known as JJP-1212, its investigational potential first-in-class anti-CD89 antagonist, in patients diagnosed with Linear IgA Disease (LAD), a rare autoantibody-mediated skin disease.
Between 2018 and 2023, Dr Ivan Puah treated over 550 cases, addressing unique challenges in Singapore's multi-ethnic population. His study included diverse case profiles....
Positive Results from Phase 2a Clinical TrialStudy met its primary endpoint demonstrating safety and tolerability of ifetroban in patients with high-risk solid tumorsTrial revealed promising...